Immune Checkpoint Blockade in Glioblastoma: From Tumor Heterogeneity to Personalized Treatment

The authors discuss contributing factors that distinguish subsets of patients with glioma who may benefit from immune checkpoint blockade.
[Journal Of Clinical Investigation]
Full Article
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News